Vascular Biogenics Valuation

VBLTDelisted Stock  USD 0.16  0.01  5.88%   
Vascular Biogenics seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Vascular Biogenics from inspecting the company fundamentals such as Shares Owned By Insiders of 13.48 %, current valuation of (10.99 M), and Return On Equity of -0.6 as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend acquiring undervalued stocks and selling overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Vascular Biogenics Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Vascular Biogenics's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Overvalued
Today
0.16
Please note that Vascular Biogenics' price fluctuation is very steady at this time. Calculation of the real value of Vascular Biogenics is based on 3 months time horizon. Increasing Vascular Biogenics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Vascular Biogenics is useful when determining the fair value of the Vascular stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Vascular Biogenics. Since Vascular Biogenics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vascular Stock. However, Vascular Biogenics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.16 Real  0.15 Hype  0.16 Naive  0.14
The real value of a stock, also known as the intrinsic value, is the underlying worth of a company that is reflected in its stock price. It is based on the company's financial performance, assets, liabilities, growth prospects, management team, industry conditions, and other relevant factors. The real value of a stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, price-to-book ratio, and other valuation metrics. The real value of a stock may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence the stock's price. It is important to note that the real value of a stock is not a fixed number and may change over time based on changes in the company's performance and other relevant factors.
0.15
Real Value
0.18
Upside
Estimating the potential upside or downside of Vascular Biogenics helps investors to forecast how Vascular stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vascular Biogenics more accurately as focusing exclusively on Vascular Biogenics' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.150.230.30
Details
Hype
Prediction
LowEstimatedHigh
0.160.160.16
Details
Naive
Forecast
LowNext ValueHigh
0.140.140.14
Details

Vascular Biogenics Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Vascular Biogenics's current stock value. Our valuation model uses many indicators to compare Vascular Biogenics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vascular Biogenics competition to find correlations between indicators driving Vascular Biogenics's intrinsic value. More Info.
Vascular Biogenics is rated first in price to book category among related companies. It is rated first in price to earning category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Vascular Biogenics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Vascular Biogenics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vascular Biogenics' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Vascular Biogenics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Vascular Biogenics and how it compares across the competition.

About Vascular Biogenics Valuation

The delisted stock valuation mechanism determines the current worth of Vascular Biogenics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Vascular Biogenics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Vascular Biogenics based exclusively on its fundamental and basic technical indicators. By analyzing Vascular Biogenics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Vascular Biogenics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Vascular Biogenics. We calculate exposure to Vascular Biogenics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Vascular Biogenics's related companies.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.

8 Steps to conduct Vascular Biogenics' Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Vascular Biogenics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Vascular Biogenics' valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Vascular Biogenics' financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Vascular Biogenics' revenue streams: Identify Vascular Biogenics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Vascular Biogenics' industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Vascular Biogenics' growth potential: Evaluate Vascular Biogenics' management, business model, and growth potential.
  • Determine Vascular Biogenics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Vascular Biogenics' estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Vascular Biogenics Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Vascular Biogenics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding77.6 M
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Consideration for investing in Vascular Stock

If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance